The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Draft Gout Guideline Released

New Draft Gout Guideline Released

November 20, 2019 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

He was prescribed 50 mg per day of allopurinol, and his dose was increased to 100 mg per day after one month until his next clinic visit. Based on a strong recommendation in the guideline to start anti-inflammatory prophylaxis, the patient also began taking colchicine at 0.6 mg per day.

You Might Also Like
  • The ACR Releases a New Gout Guideline
  • Draft Criteria for ANCA-Associated Vasculitis Released
  • New PsA Guideline Released
Explore This Issue
December 2019
Also By This Author
  • Medical Tech-Tool Usage Is Surging
Dr. Mikuls photo

Dr. Ted Mikuls

“How long should this patient remain on urate-lowering therapy? As a conditional recommendation, we recommend continuing urate-lowering therapy indefinitely over stopping urate-lowering therapy,” said Ted. R. Mikuls, MD, MSPH, Umbach Professor of Rheumatology at the University of Nebraska Medical Center and a rheumatologist at the Omaha Veterans Administration Hospital. “How long should this patient remain on colchicine prophylaxis? We strongly recommend continuing prophylaxis for at least a three-to-six-month period rather than less than three months, with ongoing evaluation, and to continue prophylaxis as needed if the patient continues to experience gout flares.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

What lifestyle management changes should a physician suggest for this patient moving forward? Based on conditional recommendations for patients with gout at any level of disease activity, physicians shouldsuggest that he limit alcohol, purine and high-fructose corn syrup intake and lose weight, but not adding vitamin C supplementation, said Dr. Mikuls.

‘We don’t have randomized trials to address every single clinical question of relevance. We need to be able to look at other evidence to help develop actionable guidelines.’ —Dr. Neogi

In another clinical scenario, a 58-year-old African American man presented to the clinic for ongoing management of his advanced gout. Three weeks after he started allopurinol therapy years ago, he experienced generalized rash, fever, eosinophilia and acute kidney injury, said N. Lawrence Edwards, MD, MACP, MACR, vice chair, graduate medical education at the University of Florida, Gainesville. The patient had no ULT for the next 14 years. His joint pain progressed. He had frequent gout flares and developed multiple tophi. He experienced gout flares every six to eight weeks. At presentation, he had low-grade synovitis in his wrists and ankles and a serum urate of 10.8 mg/dL, and his hand X-rays showed extensive erosive changes.

Dr. Edwards photo

Dr. Edwards

“Should this patient be started on a ULT? Well, you can see that he checks all the boxes for strong recommendations for starting a ULT: he has one or more subcutaneous tophi, he has radiographic damage illustrated on any modality, and he has frequent flares,” said Dr. Edwards. “Which ULT should he start? Well, he is not going to go back on allopurinol, so febuxostat. In this case, there is a strong recommendation for at starting at a low dose with subsequent dose titration to a target over starting at a higher dose and staying there.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Crystal Arthritis, Guidelines Tagged With: 2019 ACR/ARP Annual Meeting, GoutIssue: December 2019

You Might Also Like:
  • The ACR Releases a New Gout Guideline
  • Draft Criteria for ANCA-Associated Vasculitis Released
  • New PsA Guideline Released
  • The ACR Has Introduced a New Reproductive Health Guideline Draft

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)